171 related articles for article (PubMed ID: 12888267)
1. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F
J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
Li M; Ding W; Baruah B; Crans DC; Wang R
J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
[TBL] [Abstract][Full Text] [Related]
3. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
4. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
[TBL] [Abstract][Full Text] [Related]
5. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
6. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
Mohammad A; Wang J; McNeill JH
Mol Cell Biochem; 2002 Jan; 229(1-2):125-8. PubMed ID: 11936837
[TBL] [Abstract][Full Text] [Related]
7. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
Bose S; Farah MA; Jung HC; Lee JH; Kim Y
J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533
[TBL] [Abstract][Full Text] [Related]
9. Effect of vanadium on insulin sensitivity and appetite.
Wang J; Yuen VG; McNeill JH
Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of BMOV in the presence of blood serum proteins.
Sanna D; Bíró L; Buglyó P; Micera G; Garribba E
Metallomics; 2012 Jan; 4(1):33-6. PubMed ID: 22094980
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
12. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
15. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review).
Vardatsikos G; Mehdi MZ; Srivastava AK
Int J Mol Med; 2009 Sep; 24(3):303-9. PubMed ID: 19639221
[TBL] [Abstract][Full Text] [Related]
16. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry.
Nischwitz V; Davies JT; Marshall D; González M; Gómez Ariza JL; Goenaga-Infante H
Metallomics; 2013 Dec; 5(12):1685-97. PubMed ID: 24136403
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
18. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
[TBL] [Abstract][Full Text] [Related]
19. Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes.
Pereira MJ; Carvalho E; Eriksson JW; Crans DC; Aureliano M
J Inorg Biochem; 2009 Dec; 103(12):1687-92. PubMed ID: 19850351
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.
Carr AN; Davis MG; Eby-Wilkens E; Howard BW; Towne BA; Dufresne TE; Peters KG
Am J Physiol Heart Circ Physiol; 2004 Jul; 287(1):H268-76. PubMed ID: 14988069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
